Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
L. Crinò
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Amgen
D. Kim
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
G. J. Riely
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Research Funding - Pfizer
P. A. Janne
Consultant or Advisory Role - Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Genentech; Pfizer; Roche
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - Genzyme
F. H. Blackhall
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Amgen
D. R. Camidge
No relevant relationships to disclose
V. Hirsh
No relevant relationships to disclose
T. Mok
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono
B. J. Solomon
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
K. Park
Consultant or Advisory Role - Pfizer; Roche
Honoraria - AstraZeneca; Lilly; Pfizer
S. M. Gadgeel
No relevant relationships to disclose
R. Martins
Research Funding - Pfizer
Other Remuneration - Genentech; Lilly
J. Han
Honoraria - AstraZeneca
Research Funding - Bayer; Boehringer Ingelheim
T. M. De Pas
No relevant relationships to disclose
A. Bottomley
Consultant or Advisory Role - Pfizer
A. Polli
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
J. Petersen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Research Funding - Pfizer
V. R. Tassell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
A. T. Shaw
Consultant or Advisory Role - Pfizer
Research Funding - AstraZeneca; Novartis